Schwartz E, Echemendia E, Schiffer M, Panariello V A
J Clin Invest. 1969 Feb;48(2):260-70. doi: 10.1172/JCI105982.
In four acromegalic patients, estrogen therapy did not significantly alter the mean values of basal radioimmunoassayable plasma growth hormone. In two patients, estrogen therapy did not qualitatively alter the lack of reduction of plasma growth hormone levels after oral administration of glucose, nor did it reduce in these patients the response of plasma growth hormone to insulin-induced hypoglycemia. In one of the patients, insulin sensitivity with respect to glucose and the hypoglycemia-induced growth hormone rise seemed greater during estrogen therapy. Despite the absence of demonstrable reductions inplasma growth hormone level under varying experimental circumstances, the administration of estrogen resulted in reduction of urinary calcium and hydroxyproline excretion, in reduction of radiocalcium bone accretion rates and exchangeable pools, in reduction of serum phosphorus, and in more negative nitrogen balances. The experimental data therefore suggest that estrogen may be a peripheral antagonist of the effects of excessive growth hormone secretion in acromegaly.
在4例肢端肥大症患者中，雌激素治疗并未显著改变基础放射免疫法测定的血浆生长激素均值。在2例患者中，雌激素治疗并未从性质上改变口服葡萄糖后血浆生长激素水平缺乏降低的情况，也未降低这些患者血浆生长激素对胰岛素诱导的低血糖的反应。在其中1例患者中，雌激素治疗期间，对葡萄糖的胰岛素敏感性以及低血糖诱导的生长激素升高似乎更大。尽管在不同实验情况下血浆生长激素水平并无明显降低，但给予雌激素导致尿钙和羟脯氨酸排泄减少，放射性钙骨沉积率和可交换池减少，血清磷降低，以及氮平衡更负。因此，实验数据表明，雌激素可能是肢端肥大症中过量生长激素分泌作用的外周拮抗剂。
